MedTrace Logo

Home Therapy With VPRIV in Gaucher's Disease

NCT01356537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2021-03-17

No results posted yet for this study

Summary

The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.

Conditions

  • Gaucher Disease

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-20
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356537 on ClinicalTrials.gov